BlueSphere Bio

Blue Sphere Bio

Biotechnology, 100 Technology Dr, Pittsburgh, Pennsylvania, 15219, United States, 11-50 Employees

bluespherebio.com

  • twitter
  • LinkedIn

Who is BLUESPHERE BIO

BlueSphere Bio was founded to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patients own T cells for the par...

Read More

map
  • 100 Technology Dr, Pittsburgh, Pennsylvania, 15219, United States Headquarters: 100 Technology Dr, Pittsburgh, Pennsylvania, 15219, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8093

checked-icon Does something look wrong? Fix it. | View contact records from BLUESPHERE BIO

Similar Companies to BlueSphere Bio

Alnylam Pharmaceuticals

  • 1001-5000 1001-5000
  • 500 Million to 1 Billion $ 500 Million to 1 Billion

Ariel Precision Medicine

  • 11-50 11-50
  • 1 Million to 5 Million $ 1 Million to 5 Million

Novasenta

  • 11-50 11-50
  • 1 Million to 5 Million $ 1 Million to 5 Million
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding BlueSphere Bio

Answer: BlueSphere Bio's headquarters are located at 100 Technology Dr, Pittsburgh, Pennsylvania, 15219, United States

Answer: BlueSphere Bio's official website is https://bluespherebio.com

Answer: BlueSphere Bio's revenue is $25 Million to $50 Million

Answer: BlueSphere Bio's SIC: 8093

Answer: BlueSphere Bio has 11-50 employees

Answer: BlueSphere Bio is in Biotechnology

Answer: BlueSphere Bio top competitors include: Alnylam Pharmaceuticals , Ariel Precision Medicine , Novasenta

Answer: BlueSphere Bio contact info: Phone number: Website: https://bluespherebio.com

Answer: BlueSphere Bio was founded to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patients own T cells for the particular molecular fingerprint of each patients own cancer through our novel TCXpress technology. Our proprietary TCXpress platform is an elegant, rapid approach that exploits the patients own immune defenses to attack their cancer specifically, and is designed to leave normal tissues untouched, thereby reducing harmful side effects. The platform and implementation allows us to deliver rapid, personalized T cell treatments for a variety of cancer indications.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access